Tumor Necrosis Factor and Interleuktn-1 in the Serum of Children with Severe Infectious Purpura

New England Journal of Medicine

Volumn 319, Issue 7, 1988, Pages 397-400

  Girardin, Eric ^a   Grau, Georges E ^c   Dayer, Jean Michel ^b   Roux Lombard, Pascale ^b   Lambert, Paul Henri ^c  

^a Department of Paediatrics and Genetics ^*  (Switzerland)

^b Division of Immunology and Allergy   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; TUMOR NECROSIS FACTOR;

CHILD; HUMAN; MENINGOCOCCEMIA; MORTALITY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FIBRINOGEN; HUMAN; INFANT; INFANT, NEWBORN; INFECTION; INTERFERON TYPE I; INTERFERON TYPE II; INTERLEUKIN-1; PURPURA; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0023749693     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198808183190703     Document Type: Article

References (23)

1. Stiehm ER, Damrosch DS. Factors in the prognosis of meningococcal infection: review of 63 cases with emphasis on recognition and management of the severely ill patient. J Pediatr 1966; 68: 458–67.
2. Kahn A, Blum D. Factors for poor prognosis in fulminating meningococcemia: conclusions from observations of 67 childhood cases. Clin Pediatr (Phila) 1978; 17: 680–7.
3. Leclerc F, Beuscart R, Diependaele F, et al. Prognostic factors of severe infectious purpura in children. Intensive Care Med 1985; 11: 140–3.
4. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470–4.
5. Remick DG, Kunkel RG, Larrick JW, Kunkel SL. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 1987; 56: 583–90.
6. Tracey KJ, Lowry SF, Fahey TJ III, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987; 164: 415–22.
7. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307: 1225–30.
8. Washington JA. Laboratory procedures in clinical microbiology. New York: Springer-Verlag, 1981.
9. Lisi JP, Chu CW, Koch GA, Endres S, Lonnemann G, Dinarello CA. Development and use of a radioimmunoassay for human interleukin-1 β. Lymphokine Res 1987; 6: 229–44.
10. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355–7.
11. Beutler B, Milsark IW, Cerami Achéal. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869–71.
12. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379–85.
13. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481–6.
14. Grau GE, Fajardo LF, Piguet P-F, Allet B, Lamben P-H, Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 1987; 237: 1210–2.
15. Piguet P-F, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166: 1280–9.
16. Bachwich PR, Chensue SW. Larrick JW, Kunkel SL. Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. Biochem Biophys Res Commun 1986; 136: 94–101.
17. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433–50.
18. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986; 163: 1363–75.
19. Nedwin GE, Svedersky LP, Bringman TS, Palladino MA Jr. Goeddel DV. Effect of interleukin 2, interferon-γ, and mitogens on the production of tumor necrosis factors α and β. J Immunol 1985; 135: 2492–7.
20. Shalaby RM, Aggarwal BB, Rinderknecht E. Svedersky LP, Finkle BS, Palladino MA Jr. Activation of human polymorphonuclear neutrophil functions by interferon-γ and tumor necrosis factors. J Immunol 1985: 135: 2069–73.
21. Zucali JR, Elfenbein GJ, Barth KC, Dinarello CA. Effects of human interleukin 1 and human tumor necrosis factor on human T lymphocyte colony formation. J Clin Invest 1987; 80: 772–7.
22. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82: 8667–71.
23. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–4.